Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.

MLA

Wechsler, Michael E., et al. “Evaluation of the Oral Corticosteroid-Sparing Effect of Tezepelumab in Adults with Oral Corticosteroid-Dependent Asthma (SOURCE): A Randomised, Placebo-Controlled, Phase 3 Study.” Lancet Respiratory Medicine, vol. 10, no. 7, July 2022, pp. 650–60. EBSCOhost, https://doi.org/10.1016/S2213-2600(21)00537-3.

APA

Wechsler, M. E., Menzies-Gow, A., Brightling, C. E., Kuna, P., Korn, S., Welte, T., Griffiths, J. M., Sałapa, K., Hellqvist, Å., Almqvist, G., Lal, H., Kaur, P., Skärby, T., & Colice, G. (2022). Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respiratory Medicine, 10(7), 650–660. https://doi.org/10.1016/S2213-2600(21)00537-3

Chicago

Wechsler, Michael E, Andrew Menzies-Gow, Christopher E Brightling, Piotr Kuna, Stephanie Korn, Tobias Welte, Janet M Griffiths, et al. 2022. “Evaluation of the Oral Corticosteroid-Sparing Effect of Tezepelumab in Adults with Oral Corticosteroid-Dependent Asthma (SOURCE): A Randomised, Placebo-Controlled, Phase 3 Study.” Lancet Respiratory Medicine 10 (7): 650–60. doi:10.1016/S2213-2600(21)00537-3.